X4 PHARMACEUTICALS, INC Current Assets
X4 PHARMACEUTICALS, INC (XFOR) had Current Assets of $218.85 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $218.85M.
- 2026-03-31: Assets, Current $241.98M.
- 2025-12-31: Assets, Current $261.58M.
- 2025-09-30: Assets, Current $132.81M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $218.85M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $241.98M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $261.58M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $132.81M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $72.94M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $95.70M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $112.17M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $142.97M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $175.42M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $87.33M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $122.08M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $147.87M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $147.65M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $98.22M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $128.68M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $85.72M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $52.59M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $70.88M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $87.88M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $80.70M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $101.37M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $119.96M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $83.31M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $93.91M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $109.89M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $121.95M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $129.28M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $79.22M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $96.65M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $26.22M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $9.34M 10-K · filed 2020-03-12 | $35.08M 10-K · filed 2019-03-11 |
| 2018-09-30 | $44.93M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $56.56M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $68.53M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $79.53M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |